Peptides are the naturally occurring biological molecules consisting of 2 to 540 amino acids and play various crucial roles in the proper functioning of the human body.
Global Peptide Therapeutics Market & Clinical Trials Insight 2028 Report findings:
- Global Peptide Therapeutics Market Opportunity > USD 75 billion by 2028
- Global Peptide Therapeutics Clinical Trials Insight by Company, Indication & Phase
- Peptide Therapeutics in Clinical trials: > 800 Drugs
- Peptide Therapeutics Commercially Available In Market: > 200 Drugs
- Global Peptide Therapeutics Clinical Trials Insight By Peptide Type: Glucagon-like Peptides, Cyclic Peptides, Glycopeptides, Oligopeptides, Lipopeptides, Dipeptides, Opioid, Depsipeptides, Neuropeptides, Natriuretic, Bicyclic Peptides
Download Report:
https://www.pnspharma.com/reports/global-peptide-therapeutics-market-clinical-trials-insight-2028
Peptides are the naturally occurring biological molecules consisting of 2 to 540 amino acids and play various crucial roles in the proper functioning of the human body. One of the greatest discoveries in the history of medical science is related to the development of peptide hormones, including insulin, vasopressin, oxytocin, and gonadotropin‐releasing hormone and they are currently used for their potent activity such as anti‐infectives, growth factors, hormones, biological messengers, and neurotransmitters. As peptides are able to target a wide range of communicable and non-communicable diseases, they are emerging as a huge potential segment for the development of novel therapeutics. At present, more than 200 peptides are available in the market many new peptide candidates are in clinical and preclinical stage of development.
By therapeutic indication, cancer is having the dominant share in the market owing to its surge in incidences. The increased interest of the researchers can also be validated by the approval of hormonal therapy in the treatment of breast and prostate cancer as well the approval of first peptide vaccine, Sipuleucel-T in the management of prostate cancer. The peptide therapy has been widely accepted which can be depicted by the great response of peptides drugs available in the market. The market is also gathering much more attention from the researchers as there is large number of novel drugs available which are currently under clinical trial. These are expected to bring breakthrough in the cancer therapeutics market in the coming years.
More recently, collaboration between researchers at King’s College London and Academia Sinica, has led to the development of next-generation chemotherapy against triple-negative breast cancer based on peptides that pierce cell membranes, more formally referred to as membrane-perforating peptides. These are small proteins composed of just 50 amino acids. Membrane-perforating peptides work by disrupting the plasma membrane, which typically kills the targeted cells. These have shown potential in the management of triple negative breast cancer, thus driving the growth of market during the forecast period. Apart from this, more than 800 clinical trials are ongoing in global peptide therapeutics market which will drive the growth of market.
Beside the benefits of peptide therapeutics, their application as drugs is limited due to limitations such as low stability, poor membrane permeability, poor solubility, rapid clearance, low oral bioavailability, and high production costs. The traditional method for the identification of therapeutic peptides involves screening of peptide libraries, or analyzing whole proteins using overlapping window patterns in regions of peptide chains and then evaluating each part for its activity. The traditional process of drug development is time consuming, costly and laborious. These factors will hamper the growth of market during the forecast period. However, innovation in science and technology and continuous efforts by researchers will overcome these limitations during the forthcoming years.
As per our report findings, the global peptide therapeutics will surpass US$ 75 Billion by 2028. Increasing prevalence of metabolic diseases and cardiovascular disorders (CVDs) is expected to boost growth of the global peptide therapeutics market over the forecast period. Moreover, increasing healthcare expenditure is also expected to aid in growth of the market. In addition, the development of robust clinical pipeline of peptide therapeutics which is expected to gain approval in coming years will also drive the growth of market.
The report provides an in-depth analysis on peptide therapeutics market with description of market sizing and growth. The analysis includes market by value, by drug and by region. Furthermore, the report also provides detailed drug and regional analysis. Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and would be driving the growth of the industry.
Contact:
Rajesh Arora
Senior Analyst
PNS Pharma